Rossi J J, Cantin E M, Sarver N, Chang P F
Department of Molecular Genetics, Beckman Research Institute of the City of Hope, Duarte, CA 91010.
Pharmacol Ther. 1991;50(2):245-54. doi: 10.1016/0163-7258(91)90016-f.
This article describes the applications (both real and potential) of a new antiviral strategy, based on the use of antisense, catalytic RNAs (ribozymes) as therapeutic agents. An understanding of both antisense inhibition of gene expression and RNA autocleavage reactions are essential to the use of this technology. In addition, for the successful application of this technology in clinical settings, an interdisciplinary approach involving clinicians, molecular and cellular biologists, will be necessary. The following treatise will highlight several salient features of ribozyme technology, emphasizing its application as an antiviral as well as discuss some problems and potential solutions pertinent to the clinical application of this technology.
